The COVID-19 Therapeutic Answer: vascoactive intestinal peptide Zyesami stops respiratory failure in patients with severe Covid with one dose.

Cardinal Health is new distributor for Zyesami ?

The FDA received the Zyesami EUA (emergency use authorization) application 93 days ago.

Zyesami stops the replication of the Covid virus and ALL variants, including the Delta and Lambda mutations. Zyesami stops the cytokine storm.

Zyesami now manufactured at a 30 to 50 fold increase in amount produced and at a 90% decrease in manufacturing cost.

The nation of Georgia approved Zyesami EUA. 7-27-21

; Study of how Zyesami works.

Dr. Joey Johnson More news: